Figure 1
Figure 1. Survivin-specific T cells from Sur-TCR-Tg mice respond to survivin20-28 peptide. (A) CD8+ T cells from peripheral blood leukocytes of Sur-TCR-Tg mice bind survivin tetramer (gated CD8+ splenocytes are shown from E8, F8, and L8 founders and WT mice). (B) Sur-TCR-Tg CD8+ splenocytes (left panel) express high levels of CD107a following stimulation by Sur20-28 (solid line), compared with control E7 peptide (dotted line). Splenocytes from WT mice show no significant degranulation when exposed to the same peptide (right panel). (C) Expression of CD44 and TRBV8 (TCR β-variable) on gated CD8+ peripheral blood lymphocytes from WT, Sur-TCR-Tg, and Sur-TCR-Tg/Rag−/− mice. Results are shown from 1 representative mouse, and similar results were observed in >6 animals of each type.

Survivin-specific T cells from Sur-TCR-Tg mice respond to survivin20-28 peptide. (A) CD8+ T cells from peripheral blood leukocytes of Sur-TCR-Tg mice bind survivin tetramer (gated CD8+ splenocytes are shown from E8, F8, and L8 founders and WT mice). (B) Sur-TCR-Tg CD8+ splenocytes (left panel) express high levels of CD107a following stimulation by Sur20-28 (solid line), compared with control E7 peptide (dotted line). Splenocytes from WT mice show no significant degranulation when exposed to the same peptide (right panel). (C) Expression of CD44 and TRBV8 (TCR β-variable) on gated CD8+ peripheral blood lymphocytes from WT, Sur-TCR-Tg, and Sur-TCR-Tg/Rag−/− mice. Results are shown from 1 representative mouse, and similar results were observed in >6 animals of each type.

Close Modal

or Create an Account

Close Modal
Close Modal